Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

G. Schernthaner, K. Khunti, C. Lotan, M. Burnier, H. Drexel, M. Prázný,

. 2017 ; 13 (-) : 1569-1576. [pub] 20171213

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18000869

Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME® [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18000869
003      
CZ-PrNML
005      
20180123131906.0
007      
ta
008      
180116s2017 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/TCRM.S144362 $2 doi
035    __
$a (PubMed)29276388
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Schernthaner, Guntram $u Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria.
245    10
$a Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) / $c G. Schernthaner, K. Khunti, C. Lotan, M. Burnier, H. Drexel, M. Prázný,
520    9_
$a Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME® [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Khunti, Kamlesh $u Diabetes Research Centre, Leicester General Hospital, Leicester, UK.
700    1_
$a Lotan, Chaim $u Cardiovascular Division, Hadassah Medical Centre, Jerusalem, Israel.
700    1_
$a Burnier, Michel $u Division of Nephrology and Hypertension Consultation, University Hospital of Lausanne, Lausanne, Switzerland.
700    1_
$a Drexel, Heinz $u Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria.
700    1_
$a Prázný, Martin $u Charles University, Prague, Czech Republic.
773    0_
$w MED00165795 $t Therapeutics and clinical risk management $x 1176-6336 $g Roč. 13, č. - (2017), s. 1569-1576
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29276388 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180116 $b ABA008
991    __
$a 20180123132149 $b ABA008
999    __
$a ind $b bmc $g 1268264 $s 997531
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 13 $c - $d 1569-1576 $e 20171213 $i 1176-6336 $m Therapeutics and clinical risk management $n Ther. clin. risk manag. $x MED00165795
LZP    __
$a Pubmed-20180116

Find record

Citation metrics

Archiving options